Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 268.47
NPD's Cash to Debt is ranked higher than
88% of the 484 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.84 vs. NPD: 268.47 )
NPD' s 10-Year Cash to Debt Range
Min: 26.18   Max: No Debt
Current: 268.47

Equity to Asset 0.60
NPD's Equity to Asset is ranked higher than
82% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. NPD: 0.60 )
NPD' s 10-Year Equity to Asset Range
Min: 0   Max: 0.87
Current: 0.6

0
0.87
Interest Coverage No Debt
NPD's Interest Coverage is ranked higher than
93% of the 357 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.60 vs. NPD: No Debt )
NPD' s 10-Year Interest Coverage Range
Min: 17.73   Max: 9999.99
Current: No Debt

17.73
9999.99
F-Score: 6
Z-Score: 3.80
M-Score: -2.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.84
NPD's Operating margin (%) is ranked higher than
62% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. NPD: 1.84 )
NPD' s 10-Year Operating margin (%) Range
Min: -2.92   Max: 9.25
Current: 1.84

-2.92
9.25
Net-margin (%) 3.53
NPD's Net-margin (%) is ranked higher than
83% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.36 vs. NPD: 3.53 )
NPD' s 10-Year Net-margin (%) Range
Min: -2.75   Max: 8.04
Current: 3.53

-2.75
8.04
ROE (%) 8.78
NPD's ROE (%) is ranked higher than
73% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.86 vs. NPD: 8.78 )
NPD' s 10-Year ROE (%) Range
Min: -2587.18   Max: 8.78
Current: 8.78

-2587.18
8.78
ROA (%) 5.48
NPD's ROA (%) is ranked higher than
80% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.39 vs. NPD: 5.48 )
NPD' s 10-Year ROA (%) Range
Min: -5.86   Max: 5.51
Current: 5.48

-5.86
5.51
ROC (Joel Greenblatt) (%) 7.72
NPD's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.26 vs. NPD: 7.72 )
NPD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -28.68   Max: 105.02
Current: 7.72

-28.68
105.02
Revenue Growth (%) 10.10
NPD's Revenue Growth (%) is ranked higher than
88% of the 329 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.40 vs. NPD: 10.10 )
NPD' s 10-Year Revenue Growth (%) Range
Min: -11.5   Max: 58.9
Current: 10.1

-11.5
58.9
EBITDA Growth (%) -7.80
NPD's EBITDA Growth (%) is ranked higher than
62% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. NPD: -7.80 )
NPD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 122.4
Current: -7.8

0
122.4
EPS Growth (%) -9.40
NPD's EPS Growth (%) is ranked higher than
66% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.40 vs. NPD: -9.40 )
NPD' s 10-Year EPS Growth (%) Range
Min: -52.1   Max: -9.4
Current: -9.4

-52.1
-9.4
» NPD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

NPD Guru Trades in Q1 2013

Jim Simons 407,000 sh (+6.8%)
» More
Q2 2013

NPD Guru Trades in Q2 2013

Jim Simons 416,200 sh (+2.26%)
» More
Q3 2013

NPD Guru Trades in Q3 2013

Jim Simons 428,900 sh (+3.05%)
» More
Q4 2013

NPD Guru Trades in Q4 2013

Jim Simons 463,700 sh (+8.11%)
» More
» Details

Insider Trades

Latest Guru Trades with NPD



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.70
NPD's P/E(ttm) is ranked higher than
71% of the 432 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.70 vs. NPD: 18.70 )
NPD' s 10-Year P/E(ttm) Range
Min: 10.39   Max: 23549.86
Current: 18.7

10.39
23549.86
P/S 0.60
NPD's P/S is ranked higher than
56% of the 490 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. NPD: 0.60 )
NPD' s 10-Year P/S Range
Min: 0.36   Max: 6.68
Current: 0.6

0.36
6.68
EV-to-EBIT 29.40
NPD's EV-to-EBIT is ranked lower than
63% of the 457 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. NPD: 29.40 )
NPD' s 10-Year EV-to-EBIT Range
Min: 0.5   Max: 142.3
Current: 29.4

0.5
142.3
Shiller P/E 19.10
NPD's Shiller P/E is ranked higher than
75% of the 236 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.14 vs. NPD: 19.10 )
NPD' s 10-Year Shiller P/E Range
Min: 10.13   Max: 43.5
Current: 19.1

10.13
43.5

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 12.70
NPD's Dividend Yield is ranked higher than
99% of the 408 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.88 vs. NPD: 12.70 )
NPD' s 10-Year Dividend Yield Range
Min: 0.86   Max: 15.36
Current: 12.7

0.86
15.36
Dividend growth (3y) -100.00
NPD's Dividend growth (3y) is ranked higher than
62% of the 231 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. NPD: -100.00 )
NPD' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -100
Current: -100

Yield on cost (5-Year) 12.70
NPD's Yield on cost (5-Year) is ranked higher than
97% of the 415 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. NPD: 12.70 )
NPD' s 10-Year Yield on cost (5-Year) Range
Min: 0.86   Max: 15.36
Current: 12.7

0.86
15.36
Share Buyback Rate 1.80
NPD's Share Buyback Rate is ranked higher than
89% of the 271 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.10 vs. NPD: 1.80 )
NPD' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -27.1
Current: 1.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
NPD's Price/DCF (Projected) is ranked higher than
74% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. NPD: 1.20 )
NPD' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 31.92
Current: 1.2

0.79
31.92
Price/Median PS Value 0.40
NPD's Price/Median PS Value is ranked higher than
98% of the 460 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. NPD: 0.40 )
NPD' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 5.1
Current: 0.4

0.29
5.1
Earnings Yield (Greenblatt) 3.40
NPD's Earnings Yield (Greenblatt) is ranked lower than
55% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. NPD: 3.40 )
NPD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 195.3
Current: 3.4

0.7
195.3
Forward Rate of Return (Yacktman) -23.84
NPD's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.93 vs. NPD: -23.84 )
NPD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -26.7   Max: -0.5
Current: -23.84

-26.7
-0.5

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:WAG, RAD, PETS, DSCM, CVS, PERF » details
Traded in other countries:4CSA.Germany
China Nepstar Chain Drugstore Ltd. is incorporated in the Cayman Islands on August 20, 2004. Since its inception, the Company has conducted its operations in China mainly through Nepstar Pharmaceutical, which became a wholly foreign-owned enterprise in China in August 2004 as the result of its restructuring in 2004. The Company and its subsidiaries are mainly engaged in the business of operating retail drugstores in the People's Republic of China (PRC). It provides its customers with quality, professional and convenient pharmacy services and a variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. It offers various types of drinkable herbal remedies and packages of assorted herbs for making soup, which are used by consumers as health supplements. its other products include personal care products such as skin care, hair care and beauty products, family care products such as portable medical devices for family use, birth control and early pregnancy test products and convenience products, including soft drinks, packaged snacks, and other consumables, cleaning agents and stationery. Its merchandise could be classified into the following categories: Prescription Drugs, OTC Drugs, Nutritional Supplements, Herbal Products and Other Products. The Company currently sources its merchandise from regional manufacturers and wholesalers. Its typical customers are urban residents in major Chinese cities. Its sales to retail customers are paid by cash or debit or credit cards, or by medical insurance cards under the national medical insurance program. The drugstore industry in China is intensely competitive, rapidly evolving and fragmented. The Company mainly competes with other retail drugstore chains or independent drugstores. As a distributor and retailer of pharmaceutical products, the Company is subject to regulation and oversight by different levels of the food and drug administration in China, in particular, the SFDA.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide